Epilepsy, anti-seizure medication, intellectual disability and challenging behaviour – Everyone's business, no one's priority by Kinney, M. O. et al.
Contents lists available at ScienceDirect 
Seizure: European Journal of Epilepsy 
journal homepage: www.elsevier.com/locate/seizure 
Epilepsy, anti-seizure medication, intellectual disability and challenging 
behaviour – Everyone’s business, no one’s priority 
M.O. Kinneya, V. Chesterb,c, S. Tromansd,e, R.T Alexanderb,f, H. Angus-Leppang,h, M. Bagaryi,  
H. Cockj,k, J. Devapriaml, A. Hassiotism,n, M. Mulao, M. Reuberp, H. Ringq, A. Royr, M. Scheeperss,  
R. Shankart,u,* 
a Department of Neurology, The Royal Victoria Hospital (Belfast Health and Social Care Trust), Grosvenor Road, Belfast, United Kingdom 
b Department of Psychiatry, Hertfordshire Partnership University NHS Foundation Trust, Norwich, United Kingdom 
c Norwich Medical School, University of East Anglia, Norwich, United Kingdom 
d Department of Health Sciences, University of Leicester, University Road, Leicester, United Kingdom 
e Department of Intellectual Disability, Leicestershire Partnership NHS Trust, Agnes Unit, Anstey Lane, Leicester, United Kingdom 
f School of Life and Medical Sciences, University of Hertfordshire, United Kingdom 
g Epilepsy Initiative Group, Department of Clinical Neurosciences, Royal Free London NHS Foundation Trust, London, United Kingdom 
h UCL Queen Square Institute of Neurology, University College London, London, United Kingdom 
i Birmingham and Solihull Mental Health Foundation Trust, Birmingham, United Kingdom 
j Institute of Molecular and Clinical Sciences, St George’s University of London, London, United Kingdom 
k Atkinson Morley Regional Epilepsy Network, St Georges Epilepsy Group, St George’s University Hospitals NHS Foundation Trust, London, United Kingdom 
l Worcestershire Health & Care NHS Trust, 2 Kings Court, Charles Hastings Way, Worcester, United Kingdom 
m UCL Division of Psychiatry, London, United Kingdom 
n Camden & Islington NHS Foundation Trust, St Pancras Way, London, United Kingdom 
o St George’s University Hospital, St George’s University of London, United Kingdom 
p Academic Neurology Unit, University of Sheffield, Royal Hallamshire Hospital, Sheffield, United Kingdom 
q Cambridge Intellectual and Developmental Disabilities Research Group, Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom 
r Department of Psychiatry of Intellectual Disability, Coventry and Warwickshire Partnership NHS Trust, United Kingdom 
s Gloucestershire Health & Care NHS Foundation Trust, Leckhamptom Lodge, Charlton Lane, Cheltenham, Gloucestershire, United Kingdom 
t Exeter Medical School, Knowledge Spa, Truro, United Kingdom 
u Cornwall Partnership NHS Foundation Trust, Chy Govenek, Truro, United Kingdom  
A R T I C L E  I N F O   
Keywords: 
Learning disability 
Anti-seizure medication 
epilepsy 
A B S T R A C T   
Purpose: People with Intellectual Disability (ID) and epilepsy are more likely to experience psychiatric condi-
tions, challenging behaviour (CB), treatment resistance and adverse effects of anti-seizure medications (ASM) 
than those without. This population receives care from various professionals, depending on local care pathways. 
This study evaluates the training status, confidence, reported assessment and management practices of different 
professional groups involved in caring for people with ID, epilepsy and CB. 
Methods: A cross sectional survey using a questionnaire developed by expert consensus which measured self- 
reported training status, confidence, and approaches to assessment and management of CB in people with ID and 
epilepsy was distributed to practitioners involved in epilepsy and/or ID. 
Results: Of the 83 respondents, the majority had either a psychiatry/ID (n = 39), or Neurology/epileptology 
background (n = 31). Psychiatry/ID and Neurology/epileptology had similar confidence in assessing CB in ID- 
epilepsy cases, but Psychiatry/ID exhibited higher self-rated confidence in the management of these cases. While 
assessing and managing CB, Psychiatry/ID appeared more likely to consider mental health aspects, while 
Neurology/epileptology typically focused on ASM. 
Conclusion: Psychiatry/ID and Neurology/epileptology professionals had varying training levels in epilepsy, ID 
and CB, had differing confidence levels in managing this patient population, and considered different factors 
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T
when approaching assessment and management. As such, training opportunities in ID should be offered to 
neurology professionals, and vice versa. Based on the findings, a best practice checklist is presented, which aims 
to provide clinicians with a structured framework to consider causal explanations for CB in this population.   
1. Introduction 
Epilepsy is a chronic neurological disorder characterised by an en-
during predisposition to recurrent seizures, with social, biological and 
psychological consequences [1]. Epilepsy is more prevalent in persons 
with intellectual disability (ID) [2], compared to the general population 
[3]. In a cross-sectional study of 14,751 patients with ID, 18.5% had 
epilepsy compared to 0.7% of controls (Prevalence ratio 25) [4]. 
There are challenges to effectively managing epilepsy in people with 
ID, including communication issues [5], increased risks of detrimental 
effects of antiepileptic treatment [6], a lack of evidence of the effec-
tiveness of anti-seizure medications (ASMs) [7], neuropsychiatric co-
morbidity [8] and complexities assessing and managing challenging 
behaviour [9] [10]. These are difficult to individually quantify as they 
depend on the specific population and study methodology. 
Challenging behaviour is defined as culturally abnormal behaviours 
of an intensity, frequency or duration which jeopardise the safety of the 
individual or others, with possible resultant restricted access to the 
community [11]. Challenging behaviour is highly prevalent, with esti-
mates suggesting 10% of ID patients having serious challenging beha-
viours Challenging behaviours have a complex relationship to epilepsy 
which can be affected by seizure type and medication related factors as 
well as other issues [10,12–16]. 
Comorbidities of epilepsy and ID include autistic spectrum disorder 
(ASD) and attention deficit hyperactivity disorder (ADHD). A meta- 
analysis has shown a pooled prevalence of epilepsy of 21.5% in persons 
with autism and intellectual disability v. 8% in autism without in-
tellectual disability [17]. 
Care pathways for people with ID and epilepsy are fragmented, 
poorly defined, regulated and governed [18], with marked hetero-
geneity in service provision between different UK regions. The profes-
sional discipline with treatment responsibility (e.g. neurology vs. psy-
chiatry led) [18], and the context care is provided can vary widely, e.g. 
the general neurology outpatient clinic (with or without input from an 
ID psychiatrist) [18] or primary care).Relatedly, the training of ID 
psychiatrists in epilepsy and that of neurologists in ID is non-standar-
dised. In the UK, psychiatric training includes the option to specialise in 
the Psychiatry of ID, qualifying the specialist as an ID psychiatrist. 
There is a lack of clarity on training standards, competency pathways 
and expected roles [18] and variability in the level of specialism. ID 
psychiatrists are offered training in epilepsy due to its increased pre-
valence in this patient group, yet may lack specialist knowledge per-
taining to the diagnostic, investigation, and management aspects of 
seizures and the effects of ASMs [19,20]. Similarly, neurologists/epi-
leptologists may have no training in the ID-specific elements of epi-
lepsy, such as communication needs, environmental, risk, or mental 
capacity assessments, or an understanding of mental health and chal-
lenging behaviour [21]. 
It is hypothesised that different professional groups could have 
different priorities, insights, approaches, experiences, and biases re-
garding challenging behaviours. This has not been well explored in the 
ID and epilepsy context. The aims of this study were:  
1 To identify the level of training of healthcare professionals in the 
assessment/management of challenging behaviour in patients with 
ID and epilepsy.  
2 To assess confidence in assessment/management of challenging 
behaviour in patients with ID (without epilepsy) and epilepsy 
(without ID).  
3 To assess approaches in the assessment/management of challenging 
behaviour in patients with ID and co-occurring epilepsy.  
4 To develop a best practice checklist to guide professionals dealing 
with challenging behaviour in patients with ID and epilepsy. 
2. Method and Materials 
2.1. Measures and Survey Development 
The study employed a mixed methodology, including qualitative 
and quantitative elements. A 12-item questionnaire (see supplementary 
information) was developed by RS, VC and MK alongside a consultation 
panel (comprising 11 national experts of 16 invited in either: epi-
leptology, neurology, neuropsychiatry or ID; RTA, HA-L, MB, CC, JD, 
AH, MM, MR, HR, AR, MS). The survey was designed to take approxi-
mately 15 minutes to complete to facilitate a balance between ease of 
use and detailed information [22]. 
Initially, six vignettes were developed, then evaluated by the expert 
panel of clinicians and an expert by experience. After considering the 
qualitative feedback, on level of comprehension and clinical utility, two 
vignettes were taken forward for this present survey. Two final clinical 
vignettes (supplementary material) were presented within the survey. 
These vignettes were selected following development work with the 
expert panel. 
Participants were asked to indicate their confidence in the assess-
ment and management of each scenario on a five-point Likert scale from 
1 - Not at all confident, to 5 - Very confident. Respondents entered free 
text (qualitative) replies to indicate factors they would consider in their 
approach to assessment and management. 
2.2. Participants and Recruitment 
The survey was accessible via SurveyMonkey®, with a link dis-
tributed by email to the professional networks and bodies which re-
present the occupational groups involved in the care of people with ID, 
epilepsy and challenging behaviour, and representatives from these 
networks and bodies were asked to forward the survey to their mem-
bership. The sample population was therefore drawn from the mem-
bership of the International League against Epilepsy British Chapter 
(ILAE, approximately 800 members), Royal College of Psychiatrists 
Faculty of ID (n = 332), Epilepsy Nurses Association (n = 340), and 
the Association of British Neurologists (n = 800). As potential re-
spondents could be members of more than one organization the survey 
specified at the start that only one response is needed. Characteristics of 
non-responders were not available. 
2.3. Data Analysis 
Respondents (n = 70) were separated into two groups for quanti-
tative analysis; neurology/epilepsy background, and psychiatry/ID 
background. Both quantitative (categorical and ordinal) and qualitative 
data were collected in this survey. Descriptive statistics and Chi-squared 
analysis were employed. Regarding Aim 1 and 2, descriptive statistics 
and Chi-squared analysis was used to compare the psychiatry and 
neurology groups. Where the Likert scale (1-5) was analysed using Chi- 
square approach, the responses were divided into two groups. The two 
Likert points indicating confidence (very confident and partially con-
fident) were grouped, and compared to the two Likert points indicating 
low confidence (very unconfident and partially unconfident). The 2 × 2 
analysis incorporated psychiatry and neurology groups and compared 
confident and low confidence groups. 
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P value significance was initially set at < 0.05, but with 11 hy-
potheses being tested, multiple comparisons were corrected with a 
Bonferroni correction and the newly determined significance level was 
set at P < 0.0045. 
Aim three and aim four were approached using framework analysis, 
its methodology is appropriate for research that has specific questions, 
limited timeframe, pre-designed sample and a priori issues [23]. All 
respondents were included. Once key themes were assembled into a 
thematic framework, a checklist to provide a structured approach to 
causal explanations for challenging behaviour in this population was 
developed. The frequency of identified themes for different professional 
groups is presented. 
2.4. Ethics and Governance 
This project met the UK policy framework for health and social care 
research criteria for service evaluation, thus not requiring approval 
from a NHS Research Ethics Committee [24]. The survey was reviewed 
by each disseminating organization’s chair prior dissemination to their 
membership. The survey was anonymous, and did not record or store 
personal data. Consent was presumed by the return of a questionnaire 
by a participant. 
3. Results 
Eighty three responses were received, mainly from medical and 
nursing professionals (Table 1). 95% were from the UK. Respondents 
were predominantly from a psychiatry/ID (n = 39) or a neurology/ 
epilepsy background (n = 31) to include both medical and nursing 
disciplines. Respondents who did not indicate their specialism, and 
were classified as “unspecified” group (n = 13). 
3.1. Training of healthcare professionals in ID and epilepsy 
The majority of the respondents reported that they were fully qua-
lified (e.g. Consultant Psychiatrist or Registered Learning Disability 
Nurse) (n = 65, 78%), with 10 (12%) currently in training and 8 (10%) 
did not specify their level of training. The cohort had 57 (69%) re-
spondents with > 10 years clinical experience. 
Sixty two (75%) respondents reported training/specialist interest/ 
expertise in epilepsy and 44 (53%) in challenging behaviour. Eleven 
(13%) stated that they had no specialist knowledge of either. Of the 
respondents, 20/39 (51%) Psychiatry/ID professionals considered 
themselves to have expertise in both epilepsy and challenging beha-
viour, in contrast to 5/31 (16%) Neurology/epileptology (Chi squared; 
two-tailed P value, 0.0005*) (Table 1). 
3.2. Healthcare professionals confidence in the assessment and management 
of challenging behaviour in patients with ID and epilepsy 
3.2.1. Background confidence 
Psychiatry and neurology professionals did not differ significantly in 
their confidence in the assessment [28 (74%) v 25 (81%) respectively] 
or management [30 (77%) v 18 (58%) respectively] of epilepsy asso-
ciated with challenging behaviours (without co-occurring ID). 
For challenging behaviour in ID (without epilepsy) psychiatrist 
professionals when compared to neurology professionals rated them-
selves as more confident in the assessment [35 (90%) v 16 (51%) P = 
0.002*)] and management [13 (42%) of the Neurology/epileptology 
group (P = 0.0001*)], the result was significantly different (see sup-
plementary table). 
In their baseline confidence rating, psychiatry and neurology groups 
did show trends towards differences in their confidence in the assess-
ment (28 v 19 respectively, P 0.051) and management (26 v 14 re-
spectively, P, 0.016) of behavioural issues in epilepsy and co-occurring 
ID. With psychiatry groups showing greater confidence which after 
Bonferroni correction did not show significance. 
3.3. The factors and approaches healthcare professionals consider when 
assessing and managing challenging behaviour in patients with ID and 
epilepsy (Vignettes) 
The framework analysis indicated four overarching themes, biolo-
gical, psychological/psychiatric/behavioural (mental health factors), 
social and medication-related factors (Table 2). Numerical results from 
summated themes per professional grouping are included in Table 3. 
Biological and social factors were considered equally between psy-
chiatry and neurology groups, mental health factors were considered 
more frequently by psychiatry group and ASM related factors more 
frequently by neurology group (Table 3). Detailed statistical analysis for 
this aspect was not considered appropriate. 
4. Discussion 
This is the first UK based evaluation of healthcare professional’s 
approaches to those with epilepsy/ID and challenging behaviours. The 
findings highlight differences in training, levels of confidence, and in 
assessment and management of the same vignettes. Neurology/epi-
leptology professionals report less training in ID or challenging beha-
viour, were less confident in this area and didn’t consider CB part of 
their skill set. They appeared more likely to attribute challenging be-
haviour to medication factors, in comparison to psychiatry colleagues 
who considered a broader range of factors, such as behavioural and 
psychiatric factors. Both groups considered biological and social factors 
to a similar extent. These findings are aligned with previous research 
which call for epileptologists to have enhanced psychiatric/behavioural 
neurology training [21,25]. An ILAE survey of 211 participants from 35 
countries found > 60% of adult neurologists self-rated their knowledge 
of neurodevelopmental disabilities (Attention Deficit Hyperactivity 
Table 1 
Professional disciplines of respondents.       
Professional discipline N 
Nursing (n = 28) ID specialist 9 
Nurse with expertise in 
epilepsy 
10 
Unspecified 8 
ID and epilepsy nurse 
(included within 
psychiatry/ID group) 
1 
Medical/affiliated 
(n = 55) 
Neurology 
based 
Neurology 14 
Epileptology 2 
Neurology/epileptology 5 
Psychiatry 
based 
ID psychiatry Gold [15] 8 
ID psychiatry Silver [15] 3 
ID psychiatry Bronze [15] 11 
ID psychiatry (other) 3 
Neuropsychiatry 2 
Neuropsychiatry/general 
psychiatry 
1 
General psychiatry 1 
Others Clinical psychology 1 
General paediatrician 1 
General practitioner 1 
General practitioner with 
specialist interest in 
epilepsy 
2 
Self-reported 
expertise in 
epilepsy and/or 
behavioural 
assessment 
Dual skilled 
(epilepsy and 
behavioural 
assessment) n 
(%) 
Behaviour 
alone n (%) 
Epilepsy 
alone n 
(%) 
No specialist 
training in 
either n (%) 
Psychiatry/ID (n = 
39) 
20 (51%) 9 (23%) 2 (5%) 8 (21%) 
Neurology/epilepsy 
(n = 31) 
5 (16%) 0 (0%) 24 (77%) 2 (7%) 
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Disorder or Autism) as poor [21]. 
The apparent focus of epilepsy specialists on the seizure disorder 
perhaps reflects historical factors [25], and has resulted in a recent call 
for epilepsy specialists to consider standardized assessments of patients 
with ID and to factor in their comorbidities [26]. 
Our study findings have themes relevant to; clinical practice, 
training, policy development, and future research. 
4.1. Implications for clinical practice 
This work confirms clinicians can consider the same scenario dif-
ferently depending on multiple factors including their professional 
training, which will impact on care processes in this vulnerable patient 
group. Clinicians should be mindful that “expectations” they will act in 
a certain way does not make it necessarily the best option i.e. 
Table 2 
Assessing and managing challenging behaviour in a person with ID and epilepsy: framework analysis and checklist    
Theme   
Biological factors - history taking, clinical examination 
and physical investigations  
• Explore the history of the presenting complaint (with a focus on antecedent factors, seizure severity, 
including brain injuries, cognitive changes).  • Work out chronology of cause and effect.  • Explore possible underlying physical aetiologies (general medical issues such as; infections, metabolic upset, 
speech and language assessment of swallow, gut health check including stool chart evaluation, gastrointestinal 
symptoms, feeding regime/appetite (including relationship to meals), pain assessment, dental assessment, 
sleep evaluation, neurodegenerative disease, review other co-morbidities, including a review for possible 
trauma/injury).  • Complete biological investigations; blood testing (anti-seizure medication levels to assess compliance or 
toxicity), electroencephalography with comparison to previous electroencephalography results, video- 
telemetry, neuroimaging, lumbar puncture results, and video of any events/seizure diary.  • Complete bowel charts and urine dipstick.  • Measure weight (weight could be altering pharmacokinetics).  • Assess analgesia needs.  • Measure vital signs. 
Mental health/psychological/psychiatric/ behavioural 
factors  
• Complete a mental state examination/clinical psychology/ neuropsychiatry/neuropsychology assessment to 
explore for underlying/new psychiatric disorders such as depression, anxiety, autistic spectrum disorder, 
obsessive compulsive disorder).  • Consider other factors, such as the patient’s insight into their behaviours and the impact it has on others,  • Boredom/engagement/occupational therapy needs, forced normalisation, bereavement, sensory issues.  • Complete a detailed behavioural assessment (e.g. positive behavioural support/functional analysis) with 
intellectual disability team.  • Consider the need for positive behavioural support plan amendments, de-escalation strategies, anger 
management strategies and cognitive behavioural therapy.  • Consider communication factors and refer for speech and language support if relevant. 
Social factors  • Consider issues within social network, e.g. difficulties with friends or family. This will required detailed 
collateral history from other professionals and carers, particularly if the patient has communication 
difficulties.  • Consider environmental or life circumstances changes, e.g. /routine/social situation/carers), quality of life, 
levels of independence, sexual issues, trauma, vocational and recreational needs, whether the current care 
package is adequate, evaluate the living situation, e.g. whether others in the residential environment are 
affecting the patient’s mental health.  • Impact assessment of seizures on family and behaviour and provide family training/support to work with 
patient.  • Consider the need for services such as outreach support or respite.  • Consider the need for social worker involvement, as well as other professionals, such as buddying, assisted 
living, or key workers, etc. 
Medication factors  • Consider relevance of any recent changes in the anti-seizure medication, or other medications. Trial small 
dose reductions in cases of possible forced normalisation.  • Consider adverse effects including neuropsychiatric effects of medications.  • Consider patient compliance with medication, factors such as medication brand change, polypharmacy, drug 
errors, interactions and contraindications.  • Have rescue medications available.  • Consider the patient’s level of understanding the risks and benefit analysis between drug side effects and the 
risk of having seizures.  • Consider the efficacy of past therapeutic approaches. 
Table 3 
Themes endorsed by healthcare professionals in each vignette scenario            
Vignette 1 Vignette 2  
Assessment Treatment Assessment Treatment  
Neurology N (%) Psychiatry N (%) Neurology N (%) Psychiatry N (%) Neurology N (%) Psychiatry N (%) Neurology N (%) Psychiatry N (%)  
Biological 8 (26) 17 (44) 10 (32) 16 (41) 28 (90) 36 (92) 24 (77) 28 (72) 
Mental health 16 (52) 28 (72) 16 (52) 26 (67) 9 (29) 14 (36) 8 (26) 15 (38) 
Social 18 (58) 17 (44) 7 (23) 14 (36) 15 (48) 17 (44) 8 (26) 11 (28) 
Medication 29 (94) 24 (62) 18 (58) 12 (31) 10 (32) 14 (36) 8 (26) 8 (21) 
NB. For each vignette only one mention of a domain (such as biological) would be counted, giving a maximum of 31 for Neurology/epileptology and 39 for 
Psychiatry/ID. Two examples within the same domain were still only counted once. Note the absolute differences in Vignettes is not as relevant as is the difference 
between professional groups.  
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epileptologists alter ASMs. 
A standardised checklist (Table 2) which contains all factors a 
clinician should reasonably consider when facing challenging beha-
viour could reduce variation in practice. Clinicians should review their 
practice against peers by looking for their clinical “Achilles heel", for 
any cognitive bias [27] in their training or their current clinical skills. 
“Anchoring bias”; and “premature closure” of diagnostic reasoning are 
pertinent in the evaluation of challenging behaviour to prevent diag-
nostic overshadowing. 
4.2. Clinical Training Implications 
Undergraduate and postgraduate curricula should consider the 
needs and deficiencies in training to date of various professional groups 
as identified in this study. The new ILAE epileptology curriculum rates 
skills in recognition and management of the needs of patients with 
epilepsy and ID as an advanced proficiency [28]. Similarly, the role of 
ID psychiatrists in the management of epilepsy has recently been clar-
ified using a gold/silver/bronze tiered competency framework (gold 
representing expert) [18]. The real world implementation is less clear, 
with a majority of ID psychiatrists being interested in working in epi-
lepsy, but identifying the barriers of training, resources and time [19]. 
Curriculum changes often target trainees, but measures to address 
the needs of working professionals are required. Professional develop-
ment alongside multidisciplinary learning and working is key. Innovate 
methods of joint working and training between ID psychiatry and 
neurology urgently need to be considered and evaluated. 
4.3. Policy Implications 
A ILAE White Paper called for better care standards and pathways, 
multidisciplinary approaches, and improved links of relevant stake-
holders to improve epilepsy care within ID settings [28]. Kerr et al [29] 
outlined an assessment framework by which patients with ID and epi-
lepsy are considered from an epilepsy, medication, psychological and 
social perspective. The present work has built on this by assessing in-
dividual expert clinician’s training and confidence in these areas. The 
current study supports the need for multi-disciplinary networks of 
clinicians and nurses from different speciality backgrounds. Appro-
priate local commissioning should be engaged for this purpose. 
4.4. Strengths and Limitations 
This is the first in-depth exploration of clinician’s training, con-
fidence, and practice regarding the assessment and management of 
behavioural challenges in patients with epilepsy and ID. We obtained a 
sample of experienced UK professionals from a multi-disciplinary 
background with long service in their respective disciplines, which fa-
cilitated a focused examination of practice in this region. 
Regarding limitations, it is difficult to generalise the findings to 
other healthcare systems with different care pathways. Varied factors 
can impact on confidence which were not evaluated, such as burn-out, 
workplace dynamics, expectations culturally about clinical skill are 
possessed by certain groups, and culture. These results are hypothesis 
generating. There was incomplete information on non-responders, and 
a small sample size (perhaps as low as 4%), for which the reason is 
unclear. Variable effort in completing the vignette free text answers is 
always possible. 
It is perhaps the case that psychiatrists and neurologists don’t have 
such different approaches, but rather working in respective silos de-
velop different approaches based on tradition and expectation. 
Neurologists given appropriate MDT access and time to resolve issues 
may have the same approach as psychiatry professionals. Access to 
MDT input, and the full clinical context, including the spectrum of se-
verity of cases of ID seen was not assessed in this survey. Confidence is 
partly a culturally developed notion and may have other exogenous 
influences such as personality, burnout, wellbeing, political or work-
place specific factors not assessed. 
Some psychiatrists reported expertise in epilepsy but not behavior 
and 8 reported expertise in neither. These responses were considered 
atypical, and it is unclear what the exact professional situations of these 
respondents were to provide further clarification. 
4.5. Research Implications 
Future research should assess the care pathways operational within 
the UK for this clinical population, as issues are likely to be particularly 
evident in geographical regions where care of those with ID and epi-
lepsy is led solely by one professional discipline, with limited joint 
working. A future survey should examine the epilepsy/ID care provision 
region by region. This will provide an indication of the areas which 
could benefit from prioritisation of a strategy to develop multi-
disciplinary working between psychiatry/ID and neurology/epi-
leptology professionals. The proposed checklist should be validated in 
future research. Little mention was made of ASD and ADHD and views 
of professionals could be the work of a future survey to see to what 
extent neurology specialists consider the diagnosis as influencing their 
decision making in epilepsy. 
5. Conclusion 
Differences in the training of psychiatry and neurology professionals 
and their clinical confidence may influence how challenging behaviours 
in ID and co-occurring epilepsy is approached. 
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